Evidence map›Paper›PMID 33577554›Full record

ArticlePloS one2021

Anti-epileptic drug topiramate upregulates TGFβ1 and SOX9 expression in primary embryonic palatal mesenchyme cells: Implications for teratogenicity.

Syed K Rafi, Jeremy P Goering, Adam J Olm-Shipman, Lauren A Hipp, Nicholas J Ernst, Nathan R Wilson, Everett G Hall, Sumedha Gunewardena, Irfan Saadi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Mechanisms of neurodevelopmental toxicity of topiramate.Critical reviews in toxicology · 2024
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Syed K RafiDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.ORCID 0000-0002-1797-1925
Jeremy P GoeringDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
Adam J Olm-ShipmanDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
Lauren A HippDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
Nicholas J ErnstDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
Nathan R WilsonDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.ORCID 0000-0002-3092-6926
Everett G HallDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
Sumedha GunewardenaDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.
Irfan SaadiDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.ORCID 0000-0002-6250-6651
University of Kansas Medical Center · US

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SUSAN J. BROWN · 2012 to 2026
$63.0M
Transgenic and Gener-Targeting CoreP20GM104936 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SAADI, IRFAN · 2012 to 2016
$10.9M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Molecular Regulation of Cell Development and Differentiation Phase III COBREP30GM122731 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI VIVIAN, JAY L · 2017 to 2021
$5.6M
The Role of SPECC1L cytoskeletal protein in craniofacial development and malformationR01DE026172 · NIDCR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SAADI, IRFAN · 2016 to 2020
$1.9M
NICHD NIH HHS U54 HD090216NIDCR NIH HHS R01 DE026172NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20 GM104936NIGMS NIH HHS P30 GM122731
6 · The paper itself

Abstract

Topiramate is an anti-epileptic drug that is commonly prescribed not just to prevent seizures but also migraine headaches, with over 8 million prescriptions dispensed annually. Topiramate use during pregnancy has been linked to significantly increased risk of babies born with orofacial clefts (OFCs). However, the exact molecular mechanism of topiramate teratogenicity is unknown. In this study, we first used an unbiased antibody array analysis to test the effect of topiramate on human embryonic palatal mesenchyme (HEPM) cells. This analysis identified 40 differentially expressed proteins, showing strong connectivity to known genes associated with orofacial clefts. However, among known OFC genes, only TGFβ1 was significantly upregulated in the antibody array analysis. Next, we validated that topiramate could increase expression of TGFβ1 and of downstream target phospho-SMAD2 in primary mouse embryonic palatal mesenchyme (MEPM) cells. Furthermore, we showed that topiramate treatment of primary MEPM cells increased expression of SOX9. SOX9 overexpression in chondrocytes is known to cause cleft palate in mouse. We propose that topiramate mediates upregulation of TGFβ1 signaling through activation of γ-aminobutyric acid (GABA) receptors in the palate. TGFβ1 and SOX9 play critical roles in orofacial morphogenesis, and their abnormal overexpression provides a plausible etiologic molecular mechanism for the teratogenic effects of topiramate.

Indexed as

AnimalsAnticonvulsantsCell LineCells, CulturedCleft LipCleft PalateGene Expression Regulation, DevelopmentalHumansMicePalateSOX9 Transcription FactorTeratogensTopiramateTransforming Growth Factor beta1Up-RegulationAnticonvulsantsSOX9 protein, humanSOX9 Transcription FactorTeratogensTGFB1 protein, humanTopiramateTransforming Growth Factor beta1

Identifiers

PMID33577554
PMCPMC7880431
OpenAlexW3126695884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.